^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TBI 1201

    i
    Other names: TBI 1201, MAGE-A4 antigen-specific TCR modified lymphocytes, MAGE-A4 antigen-specific RetroNectin TCR gene therapy, MAGE-A4 TCR-transduced T-cell therapy, TBI-1201
    Associations

    News

    Trials
    Company:
    Takara
    Drug class:
    TCR modulator, MAGE-A4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Investigator Initiated Phase 1 Study of TBI-1201 (clinicaltrials.gov)
    P1, N=18, Completed, Mie University | Recruiting --> Completed | N=12 --> 18 | Trial primary completion date: Jun 2018 --> Mar 2021
    Trial completion • Enrollment change • Trial primary completion date
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression
    |
    fludarabine IV • TBI 1201 • cyclophosphamide intravenous